Also visit us at www.birdflulabs.com and www.orlandomedsys.com

 

     

 Profile - Contact - News - Hungary - Romania - Auction - Products - Services

1996-2020
Orlando-Systems LLC and KFT All rights reserved.
Site created by DD2 Co, VM and TB.

webcounterwebsite

ORSAIR PhoenixDX 2019-nCoV Fast PCR Testing Kits, read bellow!

Mobile Biological Health or Veterinarian Epidemics Container Laboratories
Biosafety Level BSL3 for Coronavirus COVID-19, EBOLA , MERS-SARS, Avian Flu, Malaria, Hepatitis, TB and other Infectious diseases

>Also PPE systems with ORSAIR N95 Respirators and Surgical FFP2/3 Masks  

 

Our ORSAIR PhoenixDX 2019-NCOV is a real-time RT-PCR-based detection system for the 2019 Wuhan coronavirus (2019-nCoV). 2019-nCoV is considered a novel human coronavirus that is genetically distinct from the common human coronaviruses (229E, NL63, OC43, HKU1), which cause seasonal acute respiratory illness. It is also genetically distinct from the two newer human coronaviruses, MERS-CoV and SARS-CoV.

Our Test Kit (50 tests) ORSAIR PhoenixDX 2019-NCOV detects the presence of 3 different and highly specific gene sequences of 2019-nCoV: E gene, N gene and RdRP gene. All 3 assays must be tested positive to confirm the sample as 2019-nCoV-positive.

Additionally, a non-infectious positive control and a negative human extraction control are included. The positive control is used to confirm functionality of the assays and overall PCR performance, the negative human extraction control is included to evaluate the quality of the RNA isolation independently from the 2019-nCoV assays.

The first step in the detection of 2019-nCoV is the conversion of viral RNA into cDNA. Afterwards, the target sequences unique for 2019-nCoV are specifically amplified with amplification monitored in real time through the use of fluorescently labelled probes: upon incorporation into the newly amplified DNA strands, the fluorophore (FAMTM) is released and an increase in fluorescence signal can be observed. Due to the intrinsic mutation rate of coronaviruses, it is possible that mutations in the target sequence occur and accumulate over time. This can lead to false-negative results with a PCR- based detection approach.

ORSAIR PhoenixDX 2019-NCOV addresses this issue by using 3 detection assays on 3 different target sequences to minimize the chance of false-negative results caused by an altered target sequence. If samples are tested negative in one or more assays, additional complementary testing may be required. The original target sequences for 2019-nCoV are included as a non-infectious target positive control (TPC) to check the integrity of the detection assays.

Samples tested positive should always be confirmed through complementary methods and additional analysis in an independent laboratory.

3.3) SPECIMENS - HANDLING AND STORAGE

Specimens can be stored at 4°C for up to 72 hours after collection.

If a delay in extraction is expected, store specimens at -70°C or lower. Extracted nucleic acids should be stored at -70°C or lower. Do not use specimens if: they were not kept at 2-4°C (≤ 4 days) or frozen at -70°C or below. they are insufficiently labelled or lack documentation. they are not suitable for this purpose (see above for suitable sample material). the specimen volume is insufficient.

3.4) SAMPLE PREPARATION / NUCLEIC ACID EXTRACTION

The performance of RT-PCR assays strongly depends on the amount and quality of sample template RNA. It is strongly recommended to qualify and validate RNA extraction procedures for recovery and purity before testing specimens.

Suitable nucleic acid extraction systems successfully used in combination with ORSAIR PhoenixDX DETECTION KITS include: bioMérieux NucliSens® systems, QIAamp® Viral RNA Mini Kit, QIAamp® MinElute Virus Spin Kit or RNeasy® Mini Kit (QIAGEN), EZ1 DSP Virus Kit (QIAGEN), Roche MagNA Pure Compact RNA Isolation Kit, Roche MagNA Pure Compact Nucleic Acid Isolation Kit, and Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit, and Invitrogen ChargeSwitch® Total RNA Cell Kit. Store and keep residual specimens and extracted nucleic acids at -70°C.

Only thaw the number of specimen extracts that will be tested in a single day. Do not freeze/thaw extracts more than once before testing as each freeze/thaw cycle will decrease the RNA quality. It may be possible to use patient samples directly, depending on the sample type. However, this may require a prior lysis step and titration of the amount on sample that can be used without inhibiting the reaction. This procedure has not been validated, use of isolated RNA is recommended.

Please email for more information and a ask QUOTE = always indicate if you are a End-User or not and WHICH MODEL of PCR are your using?

Mr.Theo BASCH, theo.orsys@gmail.com